Background: Gynecological cancers are among the most common cancers in women and hence an important public health issue. Due to the lack of cancer awareness, variable pathology, and dearth of proper screening facilities in developing countries such as India, most women report at advanced stages, adversely affecting the prognosis and clinical outcomes. Objective: To evaluate the response of Tegafur- Uracil as metronomic chemotherapy in previously treated gynecological malignancies Methods: This retrospective clinical study is conducted in the department of Radiotherapy, Chhattisgarh Institute of Medical Sciences, Bilaspur, Chhattisgarh. The 4 year data from 1 January 2017 to 1 January 2021 of Tegafur Uracil use in gynecological cancer is collected, studied and analyzed. Results: 52 out of 62(83.8%) patients were in below 45 years age group whereas 10 out of 62(16.1%) patients belonged to >45 years age group. 48 out of 62(77.4%) patients were of carcinoma cervix, 17.7% were of carcinoma ovary and 3 patients suffered from carcinoma endometrium. At sixteen month, 37(59.6%) patients showed CR, PR was seen in 15(24.1%) patients, stable disease was seen in 5(8.06%) whereas progressive disease was found in 5(8.06%) patients. This data showed that at sixteen month 60% patients had complete response to Tegafur- Uracil whereas only 8% patient had progression of disease. Adverse Events of oral Tegafur-Uracil was observed in 27 patients, out of which Grade 1 Nausea and Vomiting was complained by 12(44.4%) patients, oral mucositis in 3(11.1%), Neutropenia 1 (3.7%), Anemia in 1(3.7%), diarrhea in 3 (11.1%), skin rash in 2(7.4%),Anorexia in 4(14.8%) and neuropathy was seen in 1(3.7) patient only. Conclusion: As a metronomic maintenance regimen, Tegafur – Uracil was well tolerated with minimal adverse effects. We suggest Tegafur–Uracil as a maintenance therapy of choice for all patients of residual and recurrent gynecological cancers.
